New Delhi, Oct 16 (UNI) Wockhardt Ltd today said it has signed a deal to sell UK-based Crawford Healthcare's acne treatment, Zindaclin in India.
The Indian market is worth Rs 168 crore for this product, company said in a statement.
''Zindaclin has proved its effectiveness in Europe and the US.
The product will greatly benefit Indian patients with its efficacy and usage pattern,'' company's Chairman Habil Khorakiwala said.
Wockhardt's India business is registering a huge growth over the years and in-licensing will be a key growth driver for the future, he added.